The DOI matches its Crossref record.
Pegylated Liposomal Doxorubicin: Metamorphosis of an Old Drug into a New Form of Chemotherapy
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Doxorubicin encapsulated in a liposome (Doxil), administrated intravenously, has been used to treat breast cancer, ovarian cancer, Kaposi's sarcoma, and other solid tumors.”
From Hyaluronic a cid–doxorubicin nanoparticles for targeted treatment of colorectal cancer (2021) · cites this paper as [69]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 76
- Lasic D. D., 1998, Medical Applications of Liposomes
- Janoff A. S., 1999, Liposomes: Rational Design
- Markman M, 1997, Drugs, 54, 1
- Alberts D. S, 1997, Oncology, 11, 1
- Lasic D., 1995, Stealth Liposomes
- 10.1007/978-3-662-22115-0 · DOI
- 10.1073/pnas.88.24.11460 · DOI · Paper page
- 10.1016/0005-2736(90)90091-2 · DOI · Paper page
- 10.1016/0014-5793(92)80947-F · DOI · Paper page
- Gabizon A., 1990, Cancer Res., 50, 6371
- Yuan F., 1995, Cancer Res., 55, 3752
- 10.1023/A:1018907715905 · DOI · Paper page
- 10.1177/096032719601500906 · doi:10.1177/096032719601500906
- 10.1016/S0169-409X(96)00476-0 · DOI · Paper page
- 10.1038/bjc.1997.84 · DOI
- 10.2165/00003495-199700544-00005 · DOI · Paper page
- 10.3109/10611869608996830 · DOI
- Hong R-L., 1999, Clin. Cancer Res., 5, 3645
- 10.3109/08982109909035551 · DOI
- 10.3109/08982109309150734 · DOI
- Working P. K., 1999, J. Pharmacol Exp. Ther., 289, 1128
- Gabizon A., 1994, Cancer Res., 54, 987
- Martin F. J, 1997, Oncology, 11, 11
- 10.1016/S0009-9236(97)90162-4 · doi:10.1016/s0009-9236(97)90162-4
- 10.1002/1097-0142(20000901)89:5<1037::AID-CNCR13>3.0.CO;2-Z · DOI · Paper page
- 10.1002/j.1552-4604.1996.tb04152.x · DOI · Paper page
- Stewart S., 1997, Oncology, 11, 33
- 10.1002/(SICI)1097-0142(19990701)86:1<72::AID-CNCR12>3.0.CO;2-1 · DOI · Paper page
- Uziely B., 1995, J. Clin. Oncol., 13, 1777, 10.1200/JCO.1995.13.7.1777 · DOI · Paper page
- Ranson M. R., 1997, J. Clin. Oncol., 15, 3185, 10.1200/JCO.1997.15.10.3185 · DOI · Paper page
- Muggia F. M., 1997, J. Clin. Oncol., 15, 987, 10.1200/JCO.1997.15.3.987 · DOI · Paper page
- Hamilton A., 1998, Breast Cancer Res. Treat., 50, 324
- 10.1007/978-3-662-22115-0_11 · DOI
- 10.1097/00001813-199801000-00005 · DOI
- 10.1006/bbrc.1994.2658 · DOI
- 10.1097/00001813-200002000-00009 · DOI
- Huang S. K., 1994, Cancer Res., 54, 2186
- 10.1007/BF00685327 · DOI
- Gill P. S., 1995, J. Clin. Oncol., 13, 996, 10.1200/JCO.1995.13.4.996 · DOI · Paper page
- Vail D. M., 1998, Clin. Cancer Res., 4, 1567
- 10.1023/A:1008216430806 · DOI · Paper page
- 10.1023/A:1008365716693 · DOI · Paper page
- 10.1093/jnci/87.20.1556 · doi:10.1093/jnci/87.20.1556
- 10.1023/A:1008364529537 · doi:10.1023/a:1008364529537
- 10.1016/S0936-6555(05)80089-5 · doi:10.1016/s0936-6555(05)80089-5
- Harrison M., 1995, J. Clin. Oncol., 13, 914, 10.1200/JCO.1995.13.4.914 · doi:10.1200/jco.1995.13.4.914
- Northfelt D. W., 1998, J. Clin. Oncol., 16, 2445, 10.1200/JCO.1998.16.7.2445 · DOI · Paper page
- Stewart S., 1998, J. Clin. Oncol., 16, 683, 10.1200/JCO.1998.16.2.683 · DOI · Paper page
- Gill P. S., 1996, J. Clin. Oncol., 14, 2353, 10.1200/JCO.1996.14.8.2353 · DOI · Paper page
- Northfelt D. W., 1997, J. Clin. Oncol., 15, 653, 10.1200/JCO.1997.15.2.653 · DOI · Paper page
- Gordon A. N., 2000, Proc. Am. Soc. Clin. Oncol., 19, 1504
- Klein P., 2000, Proc. Am. Soc. Oncol., 19, 410a
- 10.1016/S0190-9622(00)90007-0 · doi:10.1016/s0190-9622(00)90007-0
- 10.1023/A:1008386822906 · doi:10.1023/a:1008386822906
- Ellerhorst J. A., 1999, Oncol. Rep., 6, 1097
- 10.1023/A:1008439013169 · DOI
- Judson I., 1999, Proc. Am. Soc. Clin. Oncol., 18, 541a
- 10.1023/A:1008319618638 · doi:10.1023/a:1008319618638
- 10.1002/(SICI)1096-8652(199801)57:1<85::AID-AJH16>3.0.CO;2-8 · doi:10.1002/(sici)1096-8652(199801)57:1<85::aid-ajh16>3.0.co;2-8
- 10.1016/S0959-8049(99)81571-8 · doi:10.1016/s0959-8049(99)81571-8
- Langley R. E., 1998, Proc. Am. Soc. Clin. Oncol., 17, 246a
- Wasserheit C., 1999, Proc. Am. Soc. Clin. Oncol., 18, 167a
- 10.1023/A:1008323200102 · DOI
- Lokich J., 1983, J. Clin. Oncol., 1, 24, 10.1200/JCO.1983.1.1.24 · DOI
- Samuels B. L., 1987, Cancer Treat. Rep., 71, 971
- Krishna R., 1999, Anticancer Res., 19, 2885
- Cabanes A., 1999, Clin. Cancer Res., 5, 687
- Colbern G. T., 1998, Breast Cancer Res. Treat., 50, 320
- Koukourakis M. I., 1999, J. Clin. Oncol., 17, 3512, 10.1200/JCO.1999.17.11.3512 · DOI · Paper page
- Lopez de Menezes D. E., 1998, Cancer Res., 58, 3320
- 10.1016/S0168-3659(97)00236-8 · DOI · Paper page
- 10.1073/pnas.92.5.1327 · DOI · Paper page
- 10.1038/bjc.1996.625 · DOI · Paper page
- 10.3109/08982109009036010 · DOI
- 10.1016/B978-044482917-7/50035-1 · doi:10.1016/b978-044482917-7/50035-1
- Martin F. J. Medical Applications of Liposomes, D. D. Lasic, D. Papahadjopoulos. Elsevier, New York 1998; 654
Cited by
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Recent advances with liposomes as pharmaceutical carriers
Torchilin, V. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1632 · Cited by 5,282
Exploiting the enhanced permeability and retention effect for tumor targeting
Iyer, A. K., Khaled, G., Fang, J., & Maeda, H. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.07.005 · Cited by 1,846
Pharmacokinetics of Pegylated Liposomal Doxorubicin: Review of Animal and Human Studies
Gabizon, A., Shmeeda, H., & Barenholz, Y. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342050-00002 · Cited by 1,634
Self-citationIntracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects
Maruyama, K. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.09.003 · Cited by 601
Metadata
- Authors
- Gabizon, A. A.
- Venue
- Cancer Investigation
- Publisher
- Informa UK Limited
- Published
- 2001-01
- Volume
- 19
- Issue
- 4
- Pages
- 424-436
- ISSN
- 0735-7907
- 1532-4192
- Cited by
- 458
- References
- 0
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pegylated Liposomal Doxorubicin: Metamorphosis of an Old Drug into a New Form of Chemotherapy. https://app.cochat.ai/papers/10.1081/cnv-100103136
- The paper
- Gabizon, A. A. (2001). Pegylated Liposomal Doxorubicin: Metamorphosis of an Old Drug into a New Form of Chemotherapy. Cancer Investigation. https://doi.org/10.1081/cnv-100103136
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.